Annual Revenue Comparison: Biogen Inc. vs Evotec SE

A Decade of Revenue Growth: Biogen Inc. vs. Evotec SE

In the ever-evolving landscape of biotechnology, Biogen Inc. and Evotec SE have carved distinct paths over the past decade. From 2014 to 2023, Biogen Inc. consistently outperformed Evotec SE in annual revenue, showcasing its dominance in the sector. Biogen's revenue peaked in 2019, reaching approximately 14.4 billion USD, before experiencing a gradual decline to around 9.8 billion USD in 2023. This represents a 32% decrease from its peak, reflecting market challenges and strategic shifts.

Conversely, Evotec SE demonstrated a remarkable growth trajectory, with its revenue increasing by over 770% from 2014 to 2023. Starting at a modest 89 million USD in 2014, Evotec's revenue surged to nearly 781 million USD by 2023. This growth underscores Evotec's expanding influence and successful adaptation in the competitive biotech arena. The contrasting revenue trends of these two companies highlight the dynamic nature of the industry.